Skip to content

Study · Non-randomized trial · 2002

15 results

Dual effect of cerebrolysin in children with attention deficit syndrome with hyperactivity: neuroprotection and immunomodulation.

Sotnikova NY, Gromova OA, Novicova EA

Russian journal of immunology : RJI : official journal of Russian Society of Immunology1 Dec 2002

PMID12687248 (opens in a new tab)PepBankPUB-12687248
Publisher pageAsk about this study
Jump to 15 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study15

14 results from studies that gave the peptide. 12 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In children with ADSH, Cerebrolysin normalized neurological disorders.

    In plain wordsIn children with ADSH, Cerebrolysin normalized neurological disorders.

    Peptide
    Cerebrolysin
    Outcome
    Direction not reportedNeurological disorders
    Study

    n: not reported in source

    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    1 ml per 10 kg of weight · intramuscular · 1 monthAs given in this study (human).

    Source sentences

    Summary
    The administration of cerebrolysin resulted in a simultaneous normalization of neurological and immune disorders and in a reduction in the illness rate.
    1 context sentence
    Summary · context
    Cerebrolysin was administered in a dose of 1 ml per 10 kg of weight intramuscularly during 1 month.
  2. 02HumanNon-randomized trialEfficacy outcome

    In children with ADSH, Cerebrolysin normalized immune disorders.

    In plain wordsIn children with ADSH, Cerebrolysin normalized immune disorders.

    Peptide
    Cerebrolysin
    Outcome
    Direction not reportedImmune disorders
    Study

    n: not reported in source

    Outcome group
    Immune response · Immune and inflammation
    Studied dose
    1 ml per 10 kg of weight · intramuscular · 1 monthAs given in this study (human).

    Source sentences

    Summary
    The administration of cerebrolysin resulted in a simultaneous normalization of neurological and immune disorders and in a reduction in the illness rate.
    1 context sentence
    Summary · context
    Cerebrolysin was administered in a dose of 1 ml per 10 kg of weight intramuscularly during 1 month.
  3. 03HumanNon-randomized trialEfficacy outcome

    In children with ADSH, Cerebrolysin reduced the illness rate.

    In plain wordsIn children with ADSH, Cerebrolysin reduced the illness rate.

    Peptide
    Cerebrolysin
    Outcome
    DecreaseIllness rate
    Study

    n: not reported in source

    Outcome group
    Immune response · Immune and inflammation
    Studied dose
    1 ml per 10 kg of weight · intramuscular · 1 monthAs given in this study (human).

    Source sentences

    Summary
    The administration of cerebrolysin resulted in a simultaneous normalization of neurological and immune disorders and in a reduction in the illness rate.
    1 context sentence
    Summary · context
    Cerebrolysin was administered in a dose of 1 ml per 10 kg of weight intramuscularly during 1 month.
  4. 04HumanNon-randomized trialEfficacy outcome

    In children with ADSH, Cerebrolysin normalized CD4(+) cell numbers.

    In plain wordsIn children with ADSH, Cerebrolysin normalized CD4(+) cell numbers.

    Peptide
    Cerebrolysin
    Outcome
    Direction not reportedCD4(+) cell numbers
    Study

    n: not reported in source

    Outcome group
    Immune response · Immune and inflammation
    Studied dose
    1 ml per 10 kg of weight · intramuscular · 1 monthAs given in this study (human).

    Source sentences

    Summary
    In vivo it led to the normalization of the numbers of CD4(+), CD19(+), CD16(+) and CD56(+) cells and of the level of serum IgG and IgA.
    1 context sentence
    Summary · context
    Cerebrolysin was administered in a dose of 1 ml per 10 kg of weight intramuscularly during 1 month.
  5. 05HumanNon-randomized trialEfficacy outcome

    In children with ADSH, Cerebrolysin normalized CD19(+) cell numbers.

    In plain wordsIn children with ADSH, Cerebrolysin normalized CD19(+) cell numbers.

    Peptide
    Cerebrolysin
    Outcome
    Direction not reportedCD19(+) cell numbers
    Study

    n: not reported in source

    Outcome group
    Immune response · Immune and inflammation
    Studied dose
    1 ml per 10 kg of weight · intramuscular · 1 monthAs given in this study (human).

    Source sentences

    Summary
    In vivo it led to the normalization of the numbers of CD4(+), CD19(+), CD16(+) and CD56(+) cells and of the level of serum IgG and IgA.
    1 context sentence
    Summary · context
    Cerebrolysin was administered in a dose of 1 ml per 10 kg of weight intramuscularly during 1 month.
  6. 06HumanNon-randomized trialEfficacy outcome

    In children with ADSH, Cerebrolysin normalized CD16(+) cell numbers.

    In plain wordsIn children with ADSH, Cerebrolysin normalized CD16(+) cell numbers.

    Peptide
    Cerebrolysin
    Outcome
    Direction not reportedCD16(+) cell numbers
    Study

    n: not reported in source

    Outcome group
    Immune response · Immune and inflammation
    Studied dose
    1 ml per 10 kg of weight · intramuscular · 1 monthAs given in this study (human).

    Source sentences

    Summary
    In vivo it led to the normalization of the numbers of CD4(+), CD19(+), CD16(+) and CD56(+) cells and of the level of serum IgG and IgA.
    1 context sentence
    Summary · context
    Cerebrolysin was administered in a dose of 1 ml per 10 kg of weight intramuscularly during 1 month.
  7. 07HumanNon-randomized trialEfficacy outcome

    In children with ADSH, Cerebrolysin normalized CD56(+) cell numbers.

    In plain wordsIn children with ADSH, Cerebrolysin normalized CD56(+) cell numbers.

    Peptide
    Cerebrolysin
    Outcome
    Direction not reportedCD56(+) cell numbers
    Study

    n: not reported in source

    Outcome group
    Immune response · Immune and inflammation
    Studied dose
    1 ml per 10 kg of weight · intramuscular · 1 monthAs given in this study (human).

    Source sentences

    Summary
    In vivo it led to the normalization of the numbers of CD4(+), CD19(+), CD16(+) and CD56(+) cells and of the level of serum IgG and IgA.
    1 context sentence
    Summary · context
    Cerebrolysin was administered in a dose of 1 ml per 10 kg of weight intramuscularly during 1 month.
  8. 08HumanNon-randomized trialEfficacy outcome

    In children with ADSH, Cerebrolysin normalized serum IgG levels.

    In plain wordsIn children with ADSH, Cerebrolysin normalized serum IgG levels.

    Peptide
    Cerebrolysin
    Outcome
    Direction not reportedSerum IgG
    Study

    n: not reported in source

    Outcome group
    Immune response · Immune and inflammation
    Studied dose
    1 ml per 10 kg of weight · intramuscular · 1 monthAs given in this study (human).

    Source sentences

    Summary
    In vivo it led to the normalization of the numbers of CD4(+), CD19(+), CD16(+) and CD56(+) cells and of the level of serum IgG and IgA.
    1 context sentence
    Summary · context
    Cerebrolysin was administered in a dose of 1 ml per 10 kg of weight intramuscularly during 1 month.
  9. 09HumanNon-randomized trialEfficacy outcome

    In children with ADSH, Cerebrolysin normalized serum IgA levels.

    In plain wordsIn children with ADSH, Cerebrolysin normalized serum IgA levels.

    Peptide
    Cerebrolysin
    Outcome
    Direction not reportedSerum IgA
    Study

    n: not reported in source

    Outcome group
    Immune response · Immune and inflammation
    Studied dose
    1 ml per 10 kg of weight · intramuscular · 1 monthAs given in this study (human).

    Source sentences

    Summary
    In vivo it led to the normalization of the numbers of CD4(+), CD19(+), CD16(+) and CD56(+) cells and of the level of serum IgG and IgA.
    1 context sentence
    Summary · context
    Cerebrolysin was administered in a dose of 1 ml per 10 kg of weight intramuscularly during 1 month.
  10. 10HumanNon-randomized trialEfficacy outcome

    In children with ADSH, Cerebrolysin normalized HLA DR expression on CD8(+) cells.

    In plain wordsIn children with ADSH, Cerebrolysin normalized HLA DR expression on CD8(+) cells.

    Peptide
    Cerebrolysin
    Outcome
    Direction not reportedHLA DR expression on CD8(+) cells
    Study

    n: not reported in source

    Outcome group
    Immune response · Immune and inflammation
    Studied dose
    1 ml per 10 kg of weight · intramuscular · 1 monthAs given in this study (human).

    Source sentences

    Summary
    Cerebrolysin normalized the expression of HLA DR molecules on the surface of CD8(+) cells and increased the amount of CD11b(+) lymphocytes.
    1 context sentence
    Summary · context
    Cerebrolysin was administered in a dose of 1 ml per 10 kg of weight intramuscularly during 1 month.
  11. 11HumanNon-randomized trialEfficacy outcome

    In children with ADSH, Cerebrolysin increased CD11b(+) lymphocytes.

    In plain wordsIn children with ADSH, Cerebrolysin increased CD11b(+) lymphocytes.

    Peptide
    Cerebrolysin
    Outcome
    IncreaseCD11b(+) lymphocytes
    Study

    n: not reported in source

    Outcome group
    Immune response · Immune and inflammation
    Studied dose
    1 ml per 10 kg of weight · intramuscular · 1 monthAs given in this study (human).

    Source sentences

    Summary
    Cerebrolysin normalized the expression of HLA DR molecules on the surface of CD8(+) cells and increased the amount of CD11b(+) lymphocytes.
    1 context sentence
    Summary · context
    Cerebrolysin was administered in a dose of 1 ml per 10 kg of weight intramuscularly during 1 month.
  12. 12HumanNon-randomized trialEfficacy outcome

    In children with ADSH, Cerebrolysin did not affect CD95 expression.

    In plain wordsIn children with ADSH, Cerebrolysin did not change CD95 expression.

    Peptide
    Cerebrolysin
    Outcome
    No significant changeCD95 expression
    Study

    n: not reported in source

    Outcome group
    Immune response · Immune and inflammation
    Studied dose
    1 ml per 10 kg of weight · intramuscular · 1 monthAs given in this study (human).

    Source sentences

    Summary
    At the same time, it did not affect the level of CD95 molecule expression.
    1 context sentence
    Summary · context
    Cerebrolysin was administered in a dose of 1 ml per 10 kg of weight intramuscularly during 1 month.
  13. 13LabIn vitro (cells)Efficacy outcome

    In cultured lymphocytes, Cerebrolysin enhanced HLA DR expression, particularly in CD4(+) cells.

    In plain wordsIn cells, Cerebrolysin increased HLA DR activation marker expression.

    Peptide
    Cerebrolysin
    Outcome
    IncreaseHLA DR expression
    Study

    n: not reported in source

    CD45(+)CD14(-) lymphocytes
    Outcome group
    Immune response · Immune and inflammation
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In in vitro experiments cerebrolysin enhanced the expression of activation markers (HLA DR, CD25) by CD45(+)CD14(-) lymphocytes, particularly by CD4(+) cells.
  14. 14LabIn vitro (cells)Efficacy outcome

    In cultured lymphocytes, Cerebrolysin enhanced CD25 expression, particularly in CD4(+) cells.

    In plain wordsIn cells, Cerebrolysin increased CD25 activation marker expression.

    Peptide
    Cerebrolysin
    Outcome
    IncreaseCD25 expression
    Study

    n: not reported in source

    CD45(+)CD14(-) lymphocytes
    Outcome group
    Immune response · Immune and inflammation
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In in vitro experiments cerebrolysin enhanced the expression of activation markers (HLA DR, CD25) by CD45(+)CD14(-) lymphocytes, particularly by CD4(+) cells.

Studies that did not test the peptide alone1

In this study, Cerebrolysin was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Cerebrolysin.

  1. 15LabNot a test of Cerebrolysin aloneIn vitro (cell-free)Other

    In atomic emission analysis, Cerebrolysin contained trace elements described as neuroactive and antioxidant.

    In plain wordsIn lab tests, Cerebrolysin contained trace elements described as neuroactive and antioxidant.

    Peptide
    Cerebrolysin
    Outcome
    Not applicableTrace element composition
    Study

    n: not reported in source

    Cerebrolysin preparation
    Outcome group
    Product quality and purity · Pharmacology

    Source sentences

    Summary
    The atomic emission analysis of cerebrolysin detected an advantageous combination of trace elements with neuroactive and antioxidant properties.

    In this study, Cerebrolysin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Cerebrolysin.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    14 Oct 2026, 05:02 UTC

    Study results updated

  2. Version 1

    14 Oct 2026, 01:46 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.